Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Competitive Costs of Disclosure by Biotech IPOs

Competitive Costs of Disclosure by Biotech IPOs ABSTRACT This study empirically examines the impact of various competitive cost proxies on the extent of product‐related information disclosed by biotech initial public offerings (IPOs) in their prospectuses. The choice of biotech companies, which operate in a fiercely competitive environment, crystalizes the importance of competitive disclosure costs. The focus on product‐related information is aimed at a disclosure set for which potential competitive harm is a priori substantial. Our empirical analyses establish three disclosure determinants: the stage of product development, availability of patent protection, and venture capital backing. Additionally, we find the relative size of ownership retained by pre‐IPO owners to be negatively related to the extent of disclosure, as predicted by signaling models. We also document the expected inverse relation between the extent of information conveyed by the biotech IPOs and widely used measures of information asymmetry: the bid‐ask spread and quoted depth, as well as stock return volatility. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Accounting Research Wiley

Competitive Costs of Disclosure by Biotech IPOs

Loading next page...
1
 
/lp/wiley/competitive-costs-of-disclosure-by-biotech-ipos-gzc4xqBq7G

References (37)

Publisher
Wiley
Copyright
Copyright © 2004 Wiley Subscription Services, Inc., A Wiley Company
ISSN
0021-8456
eISSN
1475-679X
DOI
10.1111/j.1475-679X.2004.00140.x
Publisher site
See Article on Publisher Site

Abstract

ABSTRACT This study empirically examines the impact of various competitive cost proxies on the extent of product‐related information disclosed by biotech initial public offerings (IPOs) in their prospectuses. The choice of biotech companies, which operate in a fiercely competitive environment, crystalizes the importance of competitive disclosure costs. The focus on product‐related information is aimed at a disclosure set for which potential competitive harm is a priori substantial. Our empirical analyses establish three disclosure determinants: the stage of product development, availability of patent protection, and venture capital backing. Additionally, we find the relative size of ownership retained by pre‐IPO owners to be negatively related to the extent of disclosure, as predicted by signaling models. We also document the expected inverse relation between the extent of information conveyed by the biotech IPOs and widely used measures of information asymmetry: the bid‐ask spread and quoted depth, as well as stock return volatility.

Journal

Journal of Accounting ResearchWiley

Published: May 1, 2004

There are no references for this article.